- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05822089
Intraindividual Comparison of EMO IOLs (EMO)
October 17, 2023 updated by: Christina Leydolt, Medical University of Vienna
Comparison of Visual Outcomes of Enhanced Monofocal Intraocular Lenses
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form.
Postoperative examinations will be implemented in accordance with the approved investigational plan.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
- Procedure: phacoemulsification and intraocular lens implantation
- Procedure: phacoemulsification and intraocular lens implantation
- Procedure: phacoemulsification and intraocular lens implantation
- Procedure: phacoemulsification and intraocular lens implantation
- Procedure: phacoemulsification and intraocular lens implantation
- Procedure: phacoemulsification and intraocular lens implantation
Study Type
Interventional
Enrollment (Estimated)
283
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christina Leydolt, MD
- Phone Number: +43 (01) 40 400 79480
- Email: christina.leydolt@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria
- Recruiting
- Medical University of Vienna
-
Contact:
- Christina Leydolt, MD
- Phone Number: +4314040079480
- Email: christina.leydolt@meduniwien.ac.at
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation
- Age 50 to 100
- Visual potential in both eyes of 20/25 or better as determined by investigators estimation
- Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Exclusion Criteria:
- Preceding intraocular surgery or ocular trauma
- Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma)
- Pupil diameter < 2.0 mm (photopic)
- Laser treatment
- Uncontrolled systemic or ocular disease
- Pregnancy/Nursing
- childbearing ability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monofocal IOL I vs. enhanced monofocal IOL I
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm one (I) participants will receive a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
Experimental: Monofocal IOL II vs. enhanced monofocal IOL I
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm two (II) participants will receive a monofocal IOL (Sensar 1AAB00) vs. an enhanced monofocal IOL (ICB00)
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
Experimental: Monofocal IOL III vs. enhanced monofocal IOL II
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm three (III) participants will receive a monofocal IOL (Vivinex XY1)vs.
an enhanced monofocal IOL (Vivinex Impress).
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
Experimental: Enhanced monofocal IOL II vs. enhanced monofocal IOL II
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm four (IV) participants will receive an enhanced monofocal IOL (Vivinex Impress) bilateral with a monovision target
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
Experimental: Monofocal IOL III vs. enhanced monofocal IOL IV
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm five (V) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
Experimental: Enhanced Monofocal IOL V vs. enhanced monofocal IOL V with irregular astigmatism
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery.
In Arm five (VI) participants will receive an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed.
|
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant corrected intermediate visual acuity
Time Frame: 2-6 months
|
Primary outcome measure will be monocular distant corrected intermediate visual acuity (DCIVA) of each intraocular lens implanted.
DCIVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
|
2-6 months
|
Best-corrected distance visual acuity (BCDVA) - Acrysof IQ Vivity IOL
Time Frame: 3-5 months
|
Primary outcome measure will be monocular best-corrected distance visual acuity (BCDVA) of each intraocular lens implanted and eyes with irregular astigmatism.
BCDVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
|
3-5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christina Leydolt, MD, Medical University of Vienna
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2021
Primary Completion (Estimated)
March 31, 2024
Study Completion (Estimated)
March 31, 2024
Study Registration Dates
First Submitted
April 7, 2023
First Submitted That Met QC Criteria
April 7, 2023
First Posted (Actual)
April 20, 2023
Study Record Updates
Last Update Posted (Actual)
October 19, 2023
Last Update Submitted That Met QC Criteria
October 17, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1631/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Cataracts
-
Sun Yat-sen UniversityUnknown
-
Medical University of ViennaActive, not recruiting
-
Medical University of ViennaNot yet recruiting
-
Medical University of ViennaCompleted
-
Rupert MenapaceUnknownAge Related CataractsAustria
-
Medical University of ViennaCompleted
-
Medical University of ViennaRecruitingAstigmatism | Age Related CataractsAustria
-
Medical University of ViennaRecruitingAstigmatism | Age Related CataractsAustria
-
Livionex Inc.Completed
-
Medical University of ViennaUnknownAge Related Cataracts | Cystoid Macular EdemaAustria
Clinical Trials on phacoemulsification and intraocular lens implantation
-
Shahid Beheshti University of Medical SciencesCompletedSurrgical Induced AstigmatismIran, Islamic Republic of
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedCataract | Fuchs' Endothelial DystrophySpain
-
Medical University of ViennaTerminatedPrimary Open Angle Glaucoma | Pseudoexfoliative Glaucoma
-
Sun Yat-sen UniversityWest China Hospital; Chongqing Medical University; Shanghai General Hospital,... and other collaboratorsActive, not recruitingGlaucoma, Angle-ClosureChina
-
Second Affiliated Hospital, School of Medicine,...UnknownRecruitment of ParticipantsChina
-
Second Affiliated Hospital, School of Medicine,...UnknownSubluxation of LensChina
-
Kasr El Aini HospitalCompletedLenses, IntraocularEgypt
-
Cairo UniversityUnknown
-
Haotian LinUnknownCataract | Corneal Endothelial Keratopathy | Phacoemulfisication+IOL Implantation | Endothelial KeratopathyChina